[1] Sundaresh V, Brito JP, Wang Z, et al.  Comparative effectiveness of therapies for Graves' hyperthyroidism: a systematic review and network meta-analysis[J]. J Clin Endocrinol Metab, 2013, 98(9): 3671-3677.   doi: 10.1210/jc.2013-1954
[2] Ross DS, Burch HB, Cooper DS, et al.  2016 American thyroid association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis[J]. Thyroid, 2016, 26(10): 1343-1421.   doi: 10.1089/thy.2016.0229
[3] De Leo S, Lee SY, Braverman LE.  Hyperthyroidism[J]. Lancet, 2016, 388(10047): 906-918.   doi: 10.1016/S0140-6736(16)00278-6
[4] Schneider DF, Sonderman PE, Jones MF, et al.  Failure of radioactive iodine in the treatment of hyperthyroidism[J]. Ann Surg Oncol, 2014, 21(13): 4174-4180.   doi: 10.1245/s10434-014-3858-4
[5] Hussain YS, Hookham JC, Allahabadia A, et al.  Epidemiology, management and outcomes of Graves' disease-real life data[J]. Endocrine, 2017, 56(3): 568-578.
[6] Weetman AP.  Graves' disease[J]. N Engl J Med, 2000, 343(17): 1236-1248.   doi: 10.1056/nejm200010263431707
[7] Burch HB, Cooper DS.  Management of Graves disease: a review[J]. JAMA, 2015, 314(23): 2544-2554.   doi: 10.1001/jama.2015.16535
[8] 中华医学会核医学分会.  131I治疗格雷夫斯甲亢指南(2013版)[J]. 标记免疫分析与临床, 2014, 21(1): 92-104.   doi: 10.11748/bjmy.Issn.1006-1703.2014.01.030
Chinese Society of Nuclear Medicine.  Guidelines for 131I treatment of graves' hyperthyroidism(2013)[J]. Labeled Immunoassays Clin Med, 2014, 21(1): 92-104.   doi: 10.11748/bjmy.Issn.1006-1703.2014.01.030
[9]

陆再英, 钟南山. 内科学[M]. 7版. 北京: 人民卫生出版社, 2008: 719.

Lu ZY, Zhong NS. The physician[M]. 7th ed. Beijing: People's Health Publishing House, 2008: 719.
[10] Ross DS.  Radioiodine therapy for hyperthyroidism[J]. N Engl J Med, 2011, 364(6): 542-550.   doi: 10.1056/NEJMct1007101
[11] Da Silva JA.  Sex hormones, glucocorticoids and autoimmunity: facts and hypotheses[J]. Ann Rheum Dis, 1995, 54(1): 6-16.   doi: 10.1136/ard.54.1.6
[12] Paavonen T.  Hormonal regulation of immune responses[J]. Ann Med, 1994, 26(4): 255-258.   doi: 10.3109/07853899409147900
[13] Allahabadia A, Daykin J, Holder RL, et al.  Age and gender predict the outcome of treatment for Graves' hyperthyroidism[J]. J Clin Endocrinol Metab, 2000, 85(3): 1038-1042.   doi: 10.1210/jcem.85.3.6430
[14] Liu M, Jing DQ, Hu JS, et al.  Predictive factors of outcomes in personalized radioactive iodine (131I) treatment for Graves' disease[J]. Am J Med Sci, 2014, 348(4): 288-293.   doi: 10.1097/MAJ.0000000000000288
[15] 刘长江, 苏敏, 杨健, 等.  影响131碘治疗甲亢疗效的因素分析[J]. 广东医学院学报, 2003, 21(2): 127-129.   doi: 10.3969/j.issn.1005-4057.2003.02.012
Liu CJ, Su M, Yang J, et al.  Analysis of factors affecting the therapeutic effect of 131I in treating hyperthyroidism[J]. J Guangdong Med Coll, 2003, 21(2): 127-129.   doi: 10.3969/j.issn.1005-4057.2003.02.012
[16] Šfiligoj D, Gaberšček S, Mekjavič PJ, et al.  Factors influencing the success of radioiodine therapy in patients with Graves' disease[J]. Nucl Med Commun, 2015, 36(6): 560-565.   doi: 10.1097/mnm.0000000000000285
[17] Willegaignon J, Sapienza MT, Coura-Filho GB, et al.  Graves' disease radioiodine-therapy: choosing target absorbed doses for therapy planning[J]. Med Phys, 2014, 41(1): 012503-.   doi: 10.1118/1.4846056
[18]

袁耿彪, 赵军. 核医学临床医师手册[M]. 人民卫生出版社, 2015: 205.

Yuan GB, Zhao J. Nuclear Medicine Clinician Handbook[M]. People's Health Publishing House, 2015: 205.
[19] 马玉波, 潘懿范, 顾爱春, 等.  131I一次和分次治愈Graves病的相关因素和疗效[J]. 上海交通大学学报: 医学版, 2015, 35(1): 69-72.
Ma YB, Pan YF, Gu AC, et al.  Correlative factors and therapeutic effect of one treatment or multi-treatments to Graves disease by 131I[J]. J Shanghai Jiao Tong Univ Med Sci, 2015, 35(1): 69-72.
[20] El-Kareem MA, Derwish WA, Moustafa HM.  Response rate and factors affecting the outcome of a fixed dose of RAI-131 therapy in Graves' disease: a 10-year Egyptian experience[J]. Nucl Med Commun, 2014, 35(9): 900-907.   doi: 10.1097/MNM.0000000000000152
[21] 敬兴果, 陈显煜, 段东.  131碘治疗甲状腺功能亢进的有效半衰期分析[J]. 放射学实践, 2004, 19(5): 377-.   doi: 10.3969/j.issn.1000-0313.2004.05.022
Jing XG, Chen XY, Duan D.  Analysis on the effective half-life of 131I in treating hyperthyroidism[J]. Radiol Pract, 2004, 19(5): 377-.   doi: 10.3969/j.issn.1000-0313.2004.05.022
[22] 谢志君, 李立, 尤真明, 等.  基于个体有效半减期计算131I投入量对治疗Graves'甲亢转归的影响[J]. 第三军医大学学报, 2017, 39(21): 2131-2134.   doi: 10.16016/j.1000-5404.201706068
Xie ZJ, Li L, You ZM, et al.  Impact of 131I given dose based on individual effective half-life on Graves disease outcome: a clinical study of 201 cases[J]. J Third Mil Med Univ, 2017, 39(21): 2131-2134.   doi: 10.16016/j.1000-5404.201706068
[23] Yang DR, Xue JJ, Ma WX, et al.  Prognostic factor analysis in 325 patients with Graves' disease treated with radioiodine therapy[J]. Nucl Med Commun, 2018, 39(1): 16-21.   doi: 10.1097/MNM.0000000000000770
[24] 胡德胜, 石磊.  131I治疗Graves甲亢临床疗效分析[J]. 标记免疫分析与临床, 2015, 22(3): 171-174.   doi: 10.11748/bjmy.issn.1006-1703.2015.03.004
Hu DS, Shi L.  Therapeutic Effects of 131I Therapy for Graves' Hyperthyroidism[J]. Labeled Immunoassays Clin Med, 2015, 22(3): 171-174.   doi: 10.11748/bjmy.issn.1006-1703.2015.03.004
[25] Karyampudi A, Hamide A, Halanaik D, et al.  Radioiodine therapy in patients with Graves' disease and the effects of prior carbimazole therapy[J]. Indian J Endocrinol Metab, 2014, 18(5): 688-693.   doi: 10.4103/2230-8210.139234
[26] 郭宁, 杨珂, 林岩松, 等.  99mTcO4−甲状腺显像对甲状腺摄碘-131率测定的影响[J]. 中国医学科学院学报, 2014, 36(3): 267-270.   doi: 10.3881/j.issn.1000-503X.2014.03.007
Guo N, Yang K, Lin YS, et al.  Influence of 99mTc-pertechnetate thyroid imaging on radioactive iodine uptake[J]. Acta Acad Med Sin, 2014, 36(3): 267-270.   doi: 10.3881/j.issn.1000-503X.2014.03.007
[27] Dora JM, Machado WE, Andrade VA, et al.  Increasing the radioiodine dose does not improve cure rates in severe Graves' hyperthyroidism: a clinical trial with historical control[J]. J Thyroid Res, 2013, 2013: 958276-.   doi: 10.1155/2013/958276
[28] 禹亚丽.  探讨甲状腺自身抗体阳性甲亢病的131I治疗与甲减关系[J]. 中国继续医学教育, 2015, 7(1): 169-170.   doi: 10.3969/j.issn.1674-9308.2015.01.141
Yu YL.  The Treatment of 131I in Thyrotoxicosis with Thyroid Autoantibody Positive and the Relationship With Hypothyroidism[J]. China Contin Med Educ, 2015, 7(1): 169-170.   doi: 10.3969/j.issn.1674-9308.2015.01.141
[29] Ratnos CD, Zantut-Wittmann DE, Tambascia MA, et al.  Thyroid suppression test with L - thyroxine and [99mTc] pertechnetate[J]. Clin Endocrinol, 2000, 52(4): 471-477.   doi: 10.1046/j.1365-2265.2000.00898.x
[30] 陈燕云, 吴乃君, 于鹏, 等.  甲状腺摄碘率对131I治疗甲亢疗效的评价[J]. 华北理工大学学报: 医学版, 2019, 21(01): 32-35.   doi: 10.19539/j.cnki.2095-2694.2019.01.007
Chen YY, Wu NJ, Yu P, et al.  Evaluating thyroid uptake rate effect of 131I on treament of hyperthyroidism[J]. J North China Univ Sci Technol: Health Sci Ed, 2019, 21(01): 32-35.   doi: 10.19539/j.cnki.2095-2694.2019.01.007
[31] 刘苑红, 蒋宁一.  24小时甲状腺摄碘率对甲亢患者131I治疗效果的相关性研究[J]. 中国医药科学, 2018, 8(13): 231-233.
Liu YH, Jiang NY.  Study of the correlation between 24h thyroid iodine uptake rate and 131I treatment in patients with hyperthyroidism[J]. China Med Pharm, 2018, 8(13): 231-233.
[32] Damle N, Bal C, Kumar P, et al.  The predictive role of 24h RAIU with respect to the outcome of low fixed dose radioiodine therapy in patients with diffuse toxic goiter[J]. Hormones, 2012, 11(4): 451-457.   doi: 10.14310/horm.2002.1377
[33] de Jong JAF, Verkooijen HM, Valk GD, et al.  High failure rates after 131I therapy in Graves hyperthyroidism patients with large thyroid volumes, high iodine uptake, and high iodine turnover[J]. Clin Nucl Med, 2013, 38(6): 401-406.   doi: 10.1097/rlu.0b013e3182817c78
[34] Park SH, Hwang S, Han S, et al.  Thyroid isthmus length and iodine turnover as predictors of successful radioactive iodine therapy in patients with Graves' disease[J]. Int J Endocrinol, 2017, 2017: 7354673-.   doi: 10.1155/2017/7354673
[35] van Isselt JW, Broekhuizen-de Gast HS.  The radioiodine turnover rate as a determinant of radioiodine treatment outcome in Graves’ disease[J]. Hell J Nucl Med, 2010, 13(1): 2-5.
[36] Tian J, Kang ZS.  Iodine-131 treatment of Graves' hyperthyroidism: new means of effective half-life measurement[J]. Chin Med Pharm, 2012, 2(23): 57-58.
[37] Szumowski P, Abdelrazek S, Kociura Sawicka A, et al.  Radioiodine therapy for Graves’ disease-retrospective analysis of efficacy factors[J]. Endokrynol Pol, 2015, 66(2): 126-131.   doi: 10.5603/EP.2015.0019
[38] 徐志勇, 周嘉强, 楼岑.  Graves病患者131I治疗后转归及相关危险因素分析[J]. 中华全科医学, 2016, 14(5): 721-723.   doi: 10.16766/j.cnki.issn.1674-4152.2016.05.008
Xu ZY, Zhou JQ, Lou C.  Clinical outcome of patients with Graves disease after receiving 131I therapy and analysis of related risk factors[J]. Chin J Gen Pract, 2016, 14(5): 721-723.   doi: 10.16766/j.cnki.issn.1674-4152.2016.05.008
[39] Reinhardt MJ, Brink I, Joe AY, et al.  Radioiodine therapy in graves' disease based on tissue-absorbed dose calculations: effect of Pre-treatment thyroid volume on clinical outcome[J]. Eur J Nucl Med Mol Imaging, 2002, 29(9): 1118-1124.   doi: 10.1007/s00259-002-0877-3
[40] Şeker S, Taş I.  Determination of thyroid volume and its relation with isthmus thickness[J]. Eur J Gen Med, 2010, 7(2): 125-129.   doi: 10.29333/ejgm/82838
[41] Bartalena L, Chiovato L, Vitti P.  Management of hyperthyroidism due to Graves' disease: frequently asked questions and answers (if any)[J]. J Endocrinol Invest, 2016, 39(10): 1105-1114.   doi: 10.1007/s40618-016-0505-x
[42] Subramanian M, Baby MK, Seshadri KG.  The effect of antithyroid drug use on delaying remission in high uptake Graves' disease following radioiodine ablation[J]. Endocr Connect, 2016, 5(1): 34-40.   doi: 10.1530/EC-15-0119
[43] 杜薇.  131I治疗Graves甲亢前长时间应用抗甲状腺药物对其治愈率的影响[J]. 中国医药指南, 2019, 17(1): 132-133.   doi: 10.15912/j.cnki.gocm.2019.01.110
Du W.  The effect of long-term application of anti-thyroid drugs on the cure rate of Graves' hyperthyroidism before 131I treatment[J]. Guide China Med, 2019, 17(1): 132-133.   doi: 10.15912/j.cnki.gocm.2019.01.110
[44] 李爱珍.  抗甲状腺药物对131I治疗甲亢疗效的影响[J]. 中国医学创新, 2013, 10(3): 28-29.   doi: 10.3969/j.issn.1674-4985.2013.03.015
Li AZ.  Effect of anti-thyroid drugs on the effect of 131I on hyperthyroidism[J]. Med Innov China, 2013, 10(3): 28-29.   doi: 10.3969/j.issn.1674-4985.2013.03.015
[45] Moka D, Dietlein M, Schicha H.  Radioiodine therapy and thyrostatic drugs and iodine[J]. Eur J Nucl Med Mol Imaging, 2002, 29 Suppl 2: S486-S491.   doi: 10.1007/s00259-002-0868-4